Open access
Effectiveness of Adding GLP‐1 Receptor Agonists to SGLT2 Inhibitor Therapy in Chronic Kidney Disease: A Population Based Study
Hussain Salim
Shaheer Qureshi
G. Gulsin
H. Khan
S. Waqas
G. McCann
A. Garg
M. Shurrab
K. Khunti
Muhammad Rashid
Sep 2026 · Diabetes, obesity and metabolism · Vol 28, pp. 11755 - 11764 · 0 citations
· 31 references
Medicine
Abstract
Individually, sodium–glucose co‐transporter‐2 inhibitors (SGLT2i) and glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) have been shown to reduce major kidney and cardiovascular events in patients with chronic kidney disease (CKD). However, evidence supporting combined GLP‐1RA and SGLT2i therapy in this population remains limited.